Introduction
AREXVY is the first FDA-approved vaccine to prevent lung and lower airway infection from respiratory syncytial virus (RSV) in people 60 years and older.
- Available for people aged 60 and older
- Can be given simultaneously as a quadrivalent flu vaccine
- Only a single-dose shot is required
In a clinical study, AREXVY was
- Over 82% effective in preventing lung and lower airway infection from RSV in people aged 60 years and older;
- Over 94% effective in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease (COPD), chronic heart failure, advanced liver or kidney disease, or any chronic respiratory or pulmonary disease.
Manufacturer
GlaxoSmithKline, GSK